- Athira Pharma Announces Proposed Settlement of Stockholder Derivative Action
- Athira Pharma Reports First Quarter 2024 Financial Results and Pipeline and Business Updates
- Athira Pharma to Participate in Upcoming May Conferences
- Athira Pharma Appoints Javier San Martin, M.D., as Chief Medical Officer
- Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
- Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
- Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
- Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
- Athira Pharma Announces Publication in Frontiers in Neuroscience Highlighting Therapeutic Potential of ATH-1105 in Amyotrophic Lateral Sclerosis (ALS)
- Athira Pharma Provides 2024 Clinical Pipeline Outlook and Business Update
More ▼
Key statistics
As of last trade, Athira Pharma Inc (ATHA:NSQ) traded at 2.61, 96.25% above the 52 week low of 1.33 set on Nov 09, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.55 |
---|---|
High | 2.67 |
Low | 2.51 |
Bid | 2.60 |
Offer | 2.62 |
Previous close | 2.56 |
Average volume | 147.18k |
---|---|
Shares outstanding | 38.33m |
Free float | 31.91m |
P/E (TTM) | -- |
Market cap | 98.12m USD |
EPS (TTM) | -3.05 USD |
Data delayed at least 15 minutes, as of May 24 2024 19:16 BST.
More ▼